BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
See today's BioWorld
Home
» Other news to note for Feb. 2, 2021
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Other news to note for Feb. 2, 2021
Feb. 2, 2021
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adagene, Adamas, Adverum, Aeterna, Aikido, Annovis, Ascentage, Bharat Biotech, Biovaxys, Can-Fite, Cevec, Circ, Coherus, Engrail, Evozyne, Exelixis, Genentech, Harbour Biomed, Ilias, Immunome, Junshi, Maia, Mati, Max, Moleculin, Neurocycle, Novelion, Ocugen, Ono, Oragenics, Paragon, Probiogen, Q, Regeneron, Ribon, Rznomics, Viewpoint Molecular, Virios, X-Chem, Zebiai, Zydus.
BioWorld
Briefs
Other news to note
Coronavirus